9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Estimated reading time: < 1 min

Condition: Cancer

Estimated Enrollment: 75

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Dose-limiting toxicities and maximum tolerated dose,  Pharmacology and pharmacokinetics,  Acetylation of histones in peripheral blood, Tumor response by CT scan every 12 weeks

Interventions: entinostat,

Phase:

Study Type: Interventional

Study Design: Masking: None (Open Label), Primary Purpose: Treatment, ,

Primary Completion Date: April 2008

Completion Date: October 2008

Last  Posted Date: March 15, 2012

Location: National Naval Medical Center, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT00020579

Was this article helpful?
Dislike 0